subject: Limit drug "a very tough battle," benefiting the patients suffer drug companies - limit drugs - the pharmaceutical industries [print this page] Limit drug "a very tough battle," benefiting the patients suffer drug companies - limit drugs - the pharmaceutical industries
Each price reduction, there is a strange phenomenon, included in the ranks of lower prices Drugs Start with the market disappear, and soon another package, the name of re-appearance, and the price even higher than before. Reduced prices so "tough battle", profit is pharmaceutical companies, drug manufacturers, are damaged patients.
Various parts of China on October 22 come into force adjusted retail price of drugs, and the current retail price of more than stipulated by the Government, the prices of about 45% of the species were appropriate reduction, the average drop about 12%; about 49% of the species has not adjusted the price to continue the implementation of the current price; there are about 6% of the varieties suitable to improve the price.
Drug price cuts, this is a good thing, also appeared several times before. Drug price cuts every time, but previously, often produces a strange phenomenon, included in the ranks of lower prices of medicines, first to die??? Disappear from the market soon been for a package, change a name, After a disguised re-appearance, but also price than before. Reduced prices so "tough battle", profit is pharmaceutical companies, drug manufacturers, are damaged patients.
The moment, to prevent recurrence of such Guaixiang, when attention to three points:
To implement low-cost pharmaceutical production of a grant system. In Germany, the patient needs and affordable drugs, in Tender Determine the production of pharmaceutical companies, the pharmaceutical companies to ensure production and supply, the government established a subsidy system, when the ex-factory price and the cost of drugs there bad losses, the government will give pharmaceutical companies a certain subsidies. Meanwhile, production of cheap drugs to these pharmaceutical companies, the government has given the appropriate tax concessions to pharmaceutical companies profitable, low-cost medicines to ensure adequate market supply and sustainability.
Two pharmaceutical companies to strict examination and approval "new drugs." Encounter "bargains dead," some drugs has been able to become a face of "live" over the key is related to a lack of information tracking and feedback mechanism. If the competent authorities to drug production and management from the laws of a firm to bear in new drug approval process, then the low-cost drugs, "dead" is not that easy, "living in" the more difficult.
3 to strengthen the building of medical institutions and pharmaceutical production of public good attributes. Over the years, a number of drugs were the reason price cuts soon abandoned by the market, which is the existing pharmaceutical production in China Sell System are inseparable. The one hand, thousands of drug manufacturers in China, competition is fierce. In order to survive and develop when the price reduction unprofitable or less profitable drugs, the pharmaceutical companies allowed to "die" on the unavoidable. On the other hand control of drug sales channels, often represented in the hospital the hands of the medical institutions, most of these institutions has been dominated by state-owned enterprises. Monopoly business model that determines the choice of medical structures in a strong position when drugs, for their own interests, they are certainly prepared to select those high-profit drugs. This is also the state that drug price cuts published many times, consumers are often difficult to buy cheap in the market, the crux of the drug.
Therefore, it is imperative for doctors and medicine are two completely separate systems for medical institutions and pharmaceutical production to become a real public good, a fundamental solution to the ordinary people of coverage, the situation could not afford medicine.
